Abstract:Background: South Africa has followed a pro-generic policy since the introduction of the National Drug Policy in 1996. The selection processes in the public and private sectors have, however, remained largely disconnected, and at times contradictory. Medicines provided outside of hospitals accounted for 17% of medical aid spend in 2006, up 8.8% from the previous year. Of particular concern to funders has been the expenditure on the 27 chronic conditions listed as Prescribed Minimum Benefits. The Medical Schemes Act (No 131 of 1998) provides for the definition of Prescribed Minimum Benefits, which stipulate a package of services or care a medical scheme must provide for in its benefit design. There is pressure to reconsider these requirements in order to increase the affordability of medical scheme coverage. This study assessed the potential savings that would be achievable by substituting generics for brand name (originator) medicines listed in the chronic disease algorithms set out by the Council for Medical Schemes (CMS). Methods: All medicines listed in the 25 chronic diseases algorithms made available by the CMS were identified. Brand and generic versions were identified in the Monthly Index of Medical Specialties (MIMS, May 2006). Single exit prices inclusive of value added tax were obtained from the web site of the Pharmaceutical Blue Book and the cost per defined daily dose for one month was then calculated. Cost differentials, where available, were then identified for each medicine listed in the algorithms. Cost differentials for medicines within each algorithm were presented as the median of the difference between brand and generic medicines listed for that algorithm, and also as the median of differences between generic medicines for the same condition. Results: Three of the algorithms (diabetes insipidus, haemophilia and hypothyroidism) list medicines for which no generic equivalent was available at the time of the study. The median cost differential between brand and generic equivalents for the remaining 22 chronic conditions ranged from 19.5% (for type 1 diabetes mellitus) to 97% (for Addison's disease). Across the entire chronic disease algorithm set, 80 medicines with generic equivalents were listed for 22 conditions. The median cost differential between brand and generic versions of these 80 medicines was 49.9% (interquartile range 32.0 to 78.5%). Of all generic medicines identified, 67.5% were more than 40% cheaper, per defined daily dose (DDD) per month, than the branded version. In 16 medicines the cost differentials between generic versions were 1% or less. Some correlation between the number of generics and the size of the cost differential was apparent (correlation coefficient 0.49). There were examples of high-cost differentials in highly competitive areas of the market. Conclusions: An argument could be made for more closely aligning the process of developing the National Essential Drugs List and the development of the CMS algorithms. By being more specific about which medicines should be covered, needless expenditure on “me-too” agents of doubtful additional benefit could be avoided. Where clinically warranted, appropriate choices could be provided. Finality in respect of the pricing of medicines needs to be achieved. This applies not only to the dispensing fee but also to the proposed benchmarking process and the proposed differential between brand and generic medicines.

[Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany]

Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.

Generic substitution of antiepileptic drugs.

Prescriptions of homeopathic remedies at the expense of the German statutory health insurance from 1985 to 2021: scientific, legal and pharmacoeconomic analysis

Interpreting the Benefit and Risk Data in Between-Drug Comparisons: Illustration of the Challenges Using the Example of Mefenamic Acid versus Ibuprofen

Controlling Prescribing through "Preferred Drug" Targets—The Bavarian Experience

Examining confidential wholesale margin estimates in European countries for the price negotiation of patented drugs in Germany: a statistical model

The Agreement Between Patient and General Practitioner-Reported Drugs Observed in a Pilot cRCT

The national e-medication approaches in Germany, Switzerland and Austria: A structured comparison

Cross-national drug price comparisons with economic weights in external reference pricing in Germany

Insufficient compliance of the German Therapeutic Products Advertising Act in product catalogues of online pharmacies

How Do the Institute for Clinical and Economic Review's Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee's Assessments of Added Benefit? A Qualitative Study

Potential cost savings from generic medicines—protecting the Prescribed Minimum Benefits

Communication of Medication Nonmedical Switching Policies and Procedures by Insurance Companies: Results of an E-Survey

Discrepancies Between the Labels of Originator and Generic Pharmaceutical Products: Implications for Patient Safety

Bioequivalence, Drugs with Narrow Therapeutic Index and The Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution

Counselling with a focus on product and price transparency for over‐the‐counter headache medicines: A simulated patient study in community pharmacies in Munich, Germany

Clinical pharmacy services are reimbursed in Germany: challenges of real world implementation remain

Reasons for supply side driven drug shortages - A mixed-methods study on first-level, higher-level, and root causes from the perspective of marketing authorization holders

[Susceptibility to strategy of the drug component of the IPHCC+RxGroups classification system in a risk-adjusted morbidity compensation scheme--a conceptional and data-supported analysis]

Availability of New Medicines in the US and Germany From 2004 to 2018